NDLI: The Alteration of Dialysate Cancer Antigen 125 Concentration Under a Biocompatible Bicarbonate Peritoneal Dialysis Solution and the Preservation of the Mesothelial Cell Viability

Content Provider	Taylor & Francis Online
Author	Kriki, P. Mourvati, E. Passadakis, P. Kantartzi, K. Theodoridis, M. Panagoutsos, S. Thodis, E. Gioka, T. Vargemezis, V.
Abstract	Background. The importance to maintain the peritoneal membrane integrity for peritoneal dialysis (PD) patients by using biocompatible solutions (with low or no glucose as osmotic factor and low in glucose degradation products-GDPs, without lactate as a buffer and with normal pH) becomes progressively more evident. The aim of the present study was to investigate the clinical effects of a novel bicarbonate-based biocompatible PD fluid, evaluating the alteration in the concentrations of dialysate marker CA125, a glucoprotein indicator of mesothelial cell mass. Patients and Methods. This is a single-center, prospective cohort study of 12 stable CAPD patients (4 women, 8 men), mean age 71.3 ± of 6.01 years, mean PD duration 31.9 ± 21.33 months, treated with the usual conventional PD solutions (with increased GDPs, low pH, and lactate as a buffer system). After a six-month period, the patients changed for the next six-month period into bicarbonate PD solutions (BicaVera, Fresenius®), after which they returned into their previous schema of conventional solutions for another six months. The dialysate marker of CA125 was repeatedly estimated at the beginning of the study (T0), after six months phase with the bicarbonate solutions (T6), and at the end of study (T12), after the second six-month use of the conventional PD solutions. All the samples were taken at the end of a four-hour dwell of an exchange with PD solution 2.5% glucose. Results. The dialysate mean value of CA125 at the beginning of the study (Td0-with conventional PD solutions) was 15.07 ± 5.72U/mL. After six months with bicarbonate PD solutions, the mean CA125 value increased to 111.97 ± 66.21U/mL, while the mean values dropped again to 22.72 ± 16.06 U/mL at the end of the study, after the patients' return for another six months to the conventional solutions use. There was a statistically significant difference between the mean CA125 levels at the beginning (Td0) and the middle of the study (Td6; p = 0.00079) as well as between the mean levels of CA125 in the middle (Td6) and at the end of the study (Td12; p = 0.0014). In contrast, comparing the mean dialysate values of CA125 at the beginning (Td0) and at the end of the study (Td12), no statistically significant difference was revealed (p = 0.13). Conclusions. For the use of the bicarbonate-based PD, more biocompatible solutions for six months produced a statistically significant increase in the dialysate concentration of the mesothelial cell mass indicator CA125. The decrease at the end of the study of CA125 mean value at a level similar with that observed at the beginning, after the six-month period of the conventional PD solutions, indicates that the clinical use of the new bicarbonate-based PD solutions may have an advantageous role in the preservation of peritoneal cell mass, maintaining also the integrity and longevity of the peritoneal membrane.
Starting Page	161
Ending Page	167
Page Count	7
File Format	PDF HTM / HTML
ISSN	0886022X 15256049
DOI	10.1080/08860220701808384
Journal	Renal Failure
Volume Number	30
Issue Number	2
Language	English
Publisher	Taylor & Francis
Publisher Date	2009-07-07
Access Restriction	Open
Subject Keyword	Peritoneal dialysis Cancer antigen 125 Biocompatible solution Mesothelial cell mass Bicarbonate
Content Type	Text
Resource Type	Article
Subject	Critical Care and Intensive Care Medicine Nephrology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis (2001)

Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients

Role of mitochondrial respiratory chain complex III in high glucose peritoneal dialysate-induced hyperpermeability of HPMCs

The effectiveness of oral essential aminoacids and aminoacids containing dialysate in peritoneal dialysis

Role of mitochondrial respiratory chain complex III in high glucose peritoneal dialysate-induced hyperpermeability of HPMCs

Cancer Antigen 125 as a Biomarker in Peritoneal Dialysis: Mesothelial Cell Health or Death?

Cancer Antigen 125 As a Biomarker in Peritoneal Dialysis: Mesothelial Cell Health or Death?

Proteomic Analysis of Peritoneal Dialysate Fluid in Patients with Dialysis-Related Peritonitis

Re: Cancer Antigen 125 As a Biomarker in Peritoneal Dialysis: Mesothelial Cell Health or Death?

The Alteration of Dialysate Cancer Antigen 125 Concentration Under a Biocompatible Bicarbonate Peritoneal Dialysis Solution and the Preservation of the Mesothelial Cell Viability

Similar Documents

Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis (2001)

Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients

Role of mitochondrial respiratory chain complex III in high glucose peritoneal dialysate-induced hyperpermeability of HPMCs

The effectiveness of oral essential aminoacids and aminoacids containing dialysate in peritoneal dialysis

Role of mitochondrial respiratory chain complex III in high glucose peritoneal dialysate-induced hyperpermeability of HPMCs

Cancer Antigen 125 as a Biomarker in Peritoneal Dialysis: Mesothelial Cell Health or Death?

Cancer Antigen 125 As a Biomarker in Peritoneal Dialysis: Mesothelial Cell Health or Death?

Proteomic Analysis of Peritoneal Dialysate Fluid in Patients with Dialysis-Related Peritonitis

Re: Cancer Antigen 125 As a Biomarker in Peritoneal Dialysis: Mesothelial Cell Health or Death?

The Alteration of Dialysate Cancer Antigen 125 Concentration Under a Biocompatible Bicarbonate Peritoneal Dialysis Solution and the Preservation of the Mesothelial Cell Viability